| [1] |
Behr TM, Gotthardt M, Barth A, et al. Imaging tumors with peptide-based radioligands[J]. Q J Nucl Med, 2001, 45(2): 189-200.
|
| [2] |
Janson ET, Westlin JE, Ohrvall U, et al. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phel]-octreotide in patients with neuroendocrine tumors[J]. J Nucl Med, 2000, 41(9): 1514-1518.
|
| [3] |
Folkman J. Addressing tumor blood vessels[J]. Nature Biotechnol, 1997, 15(6): 510.
|
| [4] |
Buerkle MA,Pahernik SA, Sutter A, et al. Inhibition of the alpha-nuintegrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo[J].Br J Cancer, 2002, 86(5): 788-795.
|
| [5] |
Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins[J]. Biotechnol N Y, 1995, 13(3): 265-270.
|
| [6] |
Brower V. Tumor angiogenesis-new drugs on the block[J].Nat Biotechnol, 1999, 17: 963-968.
|
| [7] |
Roland H, Hans JW, Ute R, et al. Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor targeting[J]. J Nucl Med, 1999, 40: 1061-1071.
|
| [8] |
Su ZF, Liu G, Gupta S, et al. In vitro and in vivo evaluation of a Technetium-99m-labeled cycyclic RGD peptide as a specific marker of alpha (V)beta (3) integrin for tumor imaging[J]. Bioconjug Chem, 2002, 13(3): 561-570.
|
| [9] |
Bock M, Bruchertseifer F, Haubner R, et al. 99Tc-m 188Re-and 90Y-labeled αvβ3 antagonists: promising tracer for tumor induced angiogenesis[J]. J Nucl Med, 2000, 41(5, suppl): 41.
|
| [10] |
Roland H, Hans JW, Wolfgang A, et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-contining glycopeptide and positron emission tomography[J]. Canner Res, 2001, 61: 1781-1785.
|
| [11] |
Sivolapenko GB, skarlos D, Pectasides D, et al. Imaging of metastatic melanoma utilising a technetium-99m-labelled RGD-containing synthetic peptide[J]. Eur J Nucl Med, 1998, 25: 1383-1389.
|